BMPs and gene therapy for spinal fusion: Summary statement

Harvinder S. Sandhu, Scott D. Boden, Howard An, James Kang, James Neil Weinstein

Research output: Contribution to journalShort surveypeer-review

10 Scopus citations

Abstract

The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.

Original languageEnglish (US)
Pages (from-to)S85
JournalSpine
Volume28
Issue number15 SUPPL.
DOIs
StatePublished - Aug 1 2003

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Clinical Neurology

Fingerprint Dive into the research topics of 'BMPs and gene therapy for spinal fusion: Summary statement'. Together they form a unique fingerprint.

Cite this